rs2501401 — CNR2

CNR2 rs2501401: Immune Tuning Through the Endocannabinoid System

The CNR2 gene encodes the cannabinoid receptor 2¹¹ cannabinoid receptor 2
CB2, a G-protein coupled receptor expressed predominantly on immune cells including macrophages, B cells, T cells, and natural killer cells. Unlike its brain-dominant counterpart CB1, CB2 is the immune system's endocannabinoid tuning knob — when activated by endogenous ligands such as 2-arachidonoylglycerol (2-AG) and anandamide, it suppresses pro-inflammatory cytokine release, reduces immune cell migration into tissues, and dampens excessive immune activation. rs2501401 is an intronic variant in CNR2 that functions as a cis-eQTL²² cis-eQTL
expression quantitative trait locus — a variant that regulates how much of the nearby gene's protein gets made, with the minor A allele associated with lower CB2 expression in whole blood (G allele NES = +0.128, p = 3.02 × 10⁻⁷ in GTEx v10, meaning each G copy raises expression).

The Mechanism

Although rs2501401 does not change any amino acid in the CB2 protein, its intronic location likely affects regulatory elements — enhancers, splice regulatory sequences, or chromatin accessibility signals — that control transcriptional output of CNR2 in immune cells. The G allele (carried by ~80% of Europeans and Africans) is associated with higher CB2 expression. The A allele (minor, ~20% in Europeans but ~65% in East Asians) correlates with lower CB2 levels in blood, which may reduce the brake on inflammatory signalling. CB2 activation normally suppresses NF-κB and MAPK pathways³³ suppresses NF-κB and MAPK pathways
the molecular switches that drive cytokine production in macrophages and T cells, so lower expression could leave immune cells in a more pro-inflammatory baseline state.

The Evidence

Direct clinical association studies for rs2501401 specifically have not been published. The evidence connecting CNR2 variation to autoimmune risk comes primarily from studies of the functional coding variant Q63R (rs35761398).

A 2025 Iranian cohort study (n=240) found that CNR2 Q63R RR carriers showed >2.5-fold increased rheumatoid arthritis risk⁴⁴ CNR2 Q63R RR carriers showed >2.5-fold increased rheumatoid arthritis risk
Nateghi et al. International Journal of Genomics, 2025 under multiple inheritance models. A 2020 case-control study (n=200)⁵⁵ 2020 case-control study (n=200) in Iran reported OR 2.70 (95% CI 1.47–4.97, p=0.001) for multiple sclerosis under the dominant model for the same Q63R variant. Studies in pediatric immune thrombocytopenic purpura similarly found OR ~2.35 for the minor allele, replicating across Egyptian and Italian cohorts⁶⁶ replicating across Egyptian and Italian cohorts. In chronic HCV infection, the variant was the only independent predictor of immune-mediated disorders⁷⁷ only independent predictor of immune-mediated disorders
cryoglobulinemia, autoimmune thyroiditis, ANA positivity, p=0.005 (49.4% vs 24.1% in controls).

The eQTL relationship for rs2501401 is confirmed in GTEx whole-blood data (p = 3.02 × 10⁻⁷), establishing that this intronic variant meaningfully influences CNR2 transcript levels. Mechanistically, CB2 has been shown to directly suppress T-cell JAK/STAT signalling⁸⁸ directly suppress T-cell JAK/STAT signalling
Xiong et al. Signal Transduction and Targeted Therapy, 2022, and increased CB2 expression is seen in inflamed intestinal tissue of children with IBD, suggesting a compensatory anti-inflammatory role.

The weight of evidence places this variant's evidence level at emerging: the eQTL is statistically robust, but a direct clinical trial or large GWAS using rs2501401 as the index SNP has not been published.

Practical Actions

For people carrying the A allele (lower CB2 expression), the primary strategy is supporting endocannabinoid tone through precursor nutrients and direct CB2 agonism, combined with early monitoring of inflammatory markers. Omega-3 fatty acids (EPA and DHA) are substrates for 2-arachidonoylglycerol (2-AG) synthesis, the most abundant endogenous CB2 ligand, making omega-3 sufficiency especially relevant when receptor expression is reduced. Palmitoylethanolamide (PEA) — an endogenous CB2 agonist — has clinical trial evidence in inflammatory and neuropathic pain conditions and can supplement the reduced endocannabinoid tone directly. For those with AA genotype and a personal or family history of autoimmune disease, periodic monitoring of inflammatory markers (CRP, ESR) provides early warning before symptoms become established.

Interactions

The most relevant interaction is with the functional coding variant rs35761398 (Q63R) in the same CNR2 gene. rs35761398 changes glutamine to arginine at position 63, altering receptor signalling efficacy. Carrying both rs2501401 AA (lower expression) and rs35761398 RR (altered receptor function) could theoretically compound impaired CB2 pathway activity, though no published study has examined this specific combination. rs35761398 is the variant with direct clinical association data and should be interpreted alongside rs2501401 when available.